ForecastedClinical trial: Optional / allowed
Forecast to Publish a Notice of Funding Opportunity for SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional)
National Institutes of Health (NIH) · NIH Institute/Center · FOR-CA-25-086
Source: Grants.gov · View original posting ↗
- AwardWhat a single award can be worth — the funder's published per-award amount or floor–ceiling range.
- Amount not listed
- DeadlineFinal application due date.
- Not yet posted
- Letter of intentDue date for the letter of intent (a short pre-application some funders require or request before the full proposal).
- —
- MechanismNIH activity code — the grant type (R01 research project, R21 exploratory, K series career development, F series fellowship, …).
- —
- DurationMaximum project period for a single award.
- —
- Expected awardsHow many awards the funder anticipates making under this opportunity.
- —
- Funding cycleHow often the program accepts applications (annual, multiple cycles per year, rolling, or one-time).
- Unknown
- Open dateWhen applications open (or opened).
- Jun 16, 2025
- Total fundingThe overall pool the funder expects to commit across ALL awards under this opportunity — not what one project receives.
- —
- Clinical trialWhether proposed projects must, may, or must not include a clinical trial.
- Optional / allowed
Other
Research areas
Clinical trials
Auto-classified from the title and description (keyword-based) — may be imperfect.
Data notes: award amount not published in the source feed; administering NIH institute could not be identified from the opportunity number.